2016
Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study
Samo RN, Agha A, Shah SA, Altaf A, Memon A, Blevins M, Qian HZ, Vermund SH. Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study. PLOS ONE 2016, 11: e0147912. PMID: 26840414, PMCID: PMC4739707, DOI: 10.1371/journal.pone.0147912.Peer-Reviewed Original ResearchConceptsCase-cohort studyMale PWIDHarm reduction programsRisk reduction programsRisk factorsReduction programsNeedle/syringe exchangeProspective cohort studyMultivariable logistic regressionResource-limited settingsHistory of incarcerationCohort studyMedian ageIncidence rateSyringe exchangePWIDMale peopleYounger ageLogistic regressionYoung menMonthsKarachiMenActive outreachProgrammatic challenges
2015
Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-up as non-pregnant women and men
Aliyu MH, Blevins M, Megazzini KM, Parrish DD, Audet CM, Chan N, Odoh C, Gebi UI, Muhammad MY, Shepherd BE, Wester CW, Vermund SH. Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-up as non-pregnant women and men. International Health 2015, 7: 405-411. PMID: 26012740, PMCID: PMC4654753, DOI: 10.1093/inthealth/ihv032.Peer-Reviewed Original ResearchConceptsNon-pregnant womenPregnant womenPregnancy statusCumulative incidenceART-naïve patientsEarly ART initiationPost-ART initiationAntiretroviral therapy initiationDays of enrollmentART-naïve HIVAntiretroviral treatment initiationRural NigeriaART initiationHigher CD4Therapy initiationTreatment initiationClinical stageCox regressionPatient groupPregnant clientsHIVLTFUWomenHigh rateSex
2013
Impact of Definitions of Loss to Follow-up on Estimates of Retention, Disease Progression, and Mortality: Application to an HIV Program in Mozambique
Shepherd BE, Blevins M, Vaz LM, Moon TD, Kipp AM, José E, Ferreira FG, Vermund SH. Impact of Definitions of Loss to Follow-up on Estimates of Retention, Disease Progression, and Mortality: Application to an HIV Program in Mozambique. American Journal Of Epidemiology 2013, 178: 819-828. PMID: 23785113, PMCID: PMC3755641, DOI: 10.1093/aje/kwt030.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVisit scheduleKaplan-Meier techniqueRate of mortalityAntiretroviral therapyCumulative incidenceTreatment initiationEstimates of retentionImmunodeficiency syndromeImmunodeficiency virusHIV programsChronic diseasesDisease progressionPatient retentionImpact of definitionsHIV literatureClinical encountersStudy outcomesMortalityAIDSLTFDeathInformative censoringProgram evaluationStudy conclusions
2011
Contemporary profile of oral manifestations of HIV/AIDS and associated risk factors in a southeastern US clinic
Tamí‐Maury I, Willig J, Vermund S, Jolly P, Aban I, Hill J, Wilson CM. Contemporary profile of oral manifestations of HIV/AIDS and associated risk factors in a southeastern US clinic. Journal Of Public Health Dentistry 2011, 71: 257-264. PMID: 22320283, DOI: 10.1111/j.1752-7325.2011.00256.x.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsAntiretroviral Therapy, Highly ActiveBlack or African AmericanCandidiasis, OralCD4 Lymphocyte CountCohort StudiesFemaleFollow-Up StudiesHeterosexualityHIV InfectionsHIV-1Homosexuality, MaleHumansMaleMouth DiseasesOropharynxPharyngeal DiseasesPrevalenceRetrospective StudiesRisk FactorsSex FactorsSoutheastern United StatesViral LoadYoung AdultConceptsOral manifestationsOropharyngeal candidiasisRisk factorsUS clinicsHIV-1 RNA viral loadLow baseline CD4 countBaseline CD4 valueMean baseline CD4Active antiretroviral therapyBaseline CD4 countRNA viral loadHIV-positive individualsHIV/AIDSLogistic regression modelsBaseline CD4Antiretroviral therapyCD4 countLaboratory characteristicsRetrospective reviewCD4 valuesViral loadHIV prevalenceMean ageT cellsHAART
2009
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol
Mwinga K, Vermund SH, Chen YQ, Mwatha A, Read JS, Urassa W, Carpenetti N, Valentine M, Goldenberg RL. Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol. BMC Pediatrics 2009, 9: 49. PMID: 19664210, PMCID: PMC2746190, DOI: 10.1186/1471-2431-9-49.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsBlood Cell CountDouble-Blind MethodFemaleFollow-Up StudiesGestational AgeHematocritHemoglobinsHIVHIV InfectionsHumansIncidenceInfantInfant, NewbornMalawiNevirapinePregnancyPregnancy Complications, InfectiousRetrospective StudiesRNA, ViralTanzaniaTreatment OutcomeYoung AdultZambiaConceptsHIV infectionPregnant African womenRandomized clinical trialsTime of laborComplete laboratory dataWeeks of ageNevirapine prophylaxisChild transmissionHIV exposureWeeks' gestationHIV statusPregnant womenNewborn infantsClinical trialsPublic clinicsHIVInfantsBiochemical measurementsCaucasian populationWomenLaboratory dataNormative dataAfrican womenInfectionWeeks
2004
Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025
Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J. Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 35: 138-143. PMID: 14722445, PMCID: PMC2753236, DOI: 10.1097/00126334-200402010-00006.Peer-Reviewed Original ResearchConceptsChris Hani Baragwanath HospitalPrevention of motherHIV Type 1Solution of chlorhexidineConcentrations of chlorhexidineChild transmissionBaragwanath HospitalMaternal symptomsPrevention trialsThird trimesterClinical indicationsMaternity unitsSubjective complaintsVaginal areaWash groupType 1ChlorhexidineInfant examinationWomenSustainable interventionsTolerable concentrationInterventionMothersWashDifferent concentrations
2002
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents
Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002, 16: 2275-2284. PMID: 12441799, DOI: 10.1097/00002030-200211220-00007.Peer-Reviewed Original ResearchConceptsViral loadHLA class IHost genetic profileHIV-1-infected adolescentsHIV-1-seropositive participantsCD4 T-cell countClass IHIV-seronegative individualsT-cell countsCD4 T lymphocytesHIV-1 infectionHIV-1 pathogenesisGenetic profileClinical patient groupsAntiretroviral therapyQuarterly followMultivariable analysisHealth cohortPatient groupImmunological outcomesImmunological controlNegative HLAT lymphocytesProtective effectAdolescent care
1997
Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study.
Tuomala RE, Kalish LA, Zorilla C, Fox H, Shearer W, Landay A, Vermund SH, Landesman S, Burns D. Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study. Obstetrics And Gynecology 1997, 89: 967-74. PMID: 9170476, DOI: 10.1016/s0029-7844(97)00129-4.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countFirst postpartum yearLymphocyte countYear postpartumCell countCD8 percentagesNonpregnant cohortLymphocyte subsetsPostpartum yearHuman immunodeficiency virus-infected womenCD4/CD8 ratioInfants Transmission StudyHuman immunodeficiency virusImmediate postpartum periodCD4 percentMean CD4Nonpregnant HIVRelative CD4CD8 ratioAbsolute CD4Lymphocyte parametersNonpregnant womenImmunodeficiency virusPregnant womenPostpartum period
1992
Follow-up evaluation of cervicovaginal human papillomavirus infection in adolescents
Rosenfeld W, Rose E, Vermund S, Schreiber K, Burk R. Follow-up evaluation of cervicovaginal human papillomavirus infection in adolescents. The Journal Of Pediatrics 1992, 121: 307-311. PMID: 1322456, DOI: 10.1016/s0022-3476(05)81212-0.Peer-Reviewed Original ResearchConceptsHPV infectionCervicovaginal human papillomavirus infectionGenotype-specific HPV infectionPositive HPV test resultHPV test resultsHuman papillomavirus infectionSame HPV typeHPV DNA detectionHuman papillomavirus DNAUrban teaching hospitalCervicovaginal lavagePapillomavirus infectionHPV typesFemale patientsTeaching hospitalPapillomavirus DNASecond examinationSecond visitPatientsInfectionVisitsHPVSouthern blot hybridizationBlot hybridizationDNA detectionThe Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxis
1991
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
STUDY T, Graham N, Zeger S, Park L, Saah A, Phair J, Detels R, Vermund S, Ho M. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Lancet 1991, 338: 265-269. PMID: 1677108, DOI: 10.1016/0140-6736(91)90414-k.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAerosolsCD4-Positive T-LymphocytesEvaluation Studies as TopicFollow-Up StudiesHIV SeropositivityHIV-1HumansLeukocyte CountMalePentamidinePneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationZidovudineConceptsPneumocystis carinii pneumoniaEffect of zidovudineHIV-1 infectionPCP prophylaxisProbability of progressionLymphocytes/First episodePneumocystis carinii pneumonia prophylaxisHIV-1-infected individualsHIV-1-seropositive menMonth intervalsPrimary PCP prophylaxisEfficacy of zidovudinePresence of HIVRate of progressionMultivariate log-linear modelPneumonia prophylaxisMore CD4Primary prophylaxisZidovudine therapyLymphocyte countCarinii pneumoniaClinical trialsObservational studyProphylaxis